Dyslipidemia Global Drug Forecast 2023 Market Size, Share, Trend, Analysis, Research Report
Estimates that the total market size for the 8MM in 2013 was $15.4 bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over the ten year forecast period, resulting in a market value of $37.9bn by 2023, of which 71% will be attributed to branded drug sales ($26.9bn) and 29% to generic drug sales ($11.0 bn).
View full press release